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Histidine biosynthesis is an essential process in plants and
microorganisms, making it an attractive target for the develop-
ment of herbicides and antibacterial agents. Imidazoleglycerol-
phosphate dehydratase (IGPD), a key enzyme within this pathway,
has been biochemically characterized in both Saccharomyces cer-
evisiae (Sc_IGPD) and Arabidopsis thaliana (At_IGPD). The plant
enzyme, having been the focus of in-depth structural analysis as
part of an inhibitor development program, has revealed details
about the reaction mechanism of IGPD, whereas the yeast enzyme
has proven intractable to crystallography studies. The structure–
activity relationship of potent triazole-phosphonate inhibitors of
IGPD has been determined in both homologs, revealing that the
lead inhibitor (C348) is an order of magnitude more potent against
Sc_IGPD than At_IGPD; however, the molecular basis of this differ-
ence has not been established. Here we have used single-particle
electron microscopy (EM) to study structural differences between
the At and Sc_IGPD homologs, which could influence the differ-
ence in inhibitor potency. The resulting EM maps at ∼3 Å are
sufficient to de novo build the protein structure and identify the
inhibitor binding site, which has been validated against the crystal
structure of the At_IGPD/C348 complex. The structure of Sc_IGPD
reveals that a 24-amino acid insertion forms an extended loop
region on the enzyme surface that lies adjacent to the active site,
forming interactions with the substrate/inhibitor binding loop that
may influence inhibitor potency. Overall, this study provides in-
sights into the IGPD family and demonstrates the power of using
an EM approach to study inhibitor binding.
electron microscopy | structure-based drug design | histidine biosynthesis |
IGPD | enzyme inhibition
Imidazoleglycerol-phosphate dehydratase (IGPD) is an essen-tial enzyme in plants and microorganisms, and thus it is an
attractive target for the development of herbicides and antibac-
terial agents, for which there are presently a limited number of
biological targets. IGPD catalyzes the sixth step in histidine
biosynthesis, where manganese(II)-dependent dehydration of
imidazoleglycerol-phosphate occurs to form imidazoleacetol-
phosphate and a concomitant water (1–3). The structure of IGPD
has been well studied by X-ray crystallography in several organisms,
including the plant Arabidopsis thaliana (At_IGPD) (3), the bacterial
and archaeal species including Mycobacterium tuberculosis and Pyro-
coccus furiosus (4, 5), and the fungus Cryptococcus neoformans (6).
These studies show that the core IGPD structure is conserved, com-
prising a 24-mer with 432 symmetry with two octahedrally coordinated
Mn2+ ions in each active site. The manganese ions have been shown
to have an important role in binding the substrate and coordinating
turnover of the intermediates during the reaction (3, 7–9). Although
the majority of the early biochemical studies (8) and various herbicide
development programs have focused on IGPD from Saccharomyces
cerevisiae as a model system (Sc_IGPD), diffraction from crystals of
the enzyme has never been obtained to better than ∼6 Å resolution
(10), and the structure has not been determined. Although there is
generally high sequence homology between IGPD homologs from
different species, especially surrounding the active site, Sc_IGPD has
an intriguing sequence difference arising from a 24-amino acid in-
sertion between β2 and β3 that is only found in budding yeast.
Interestingly, the most potent lead compound that has emerged
from herbicide development, the triazole-phosphonate compound
2-hydroxy-3-(1,2,4-triazol-1-yl) (C348), is an order of magnitude
more potent against Sc_IGPD (0.6 nM Ki) (2) than At_IGPD
(∼25 nM Ki) (5). Although the mode of binding of C348 has been
well studied by X-ray crystallography in At_IGPD, the molecular
basis of this difference in potency is unknown. Understanding
differences in potency across different species is important if we
are to develop more specific and potent inhibitors of IGPD
against bacteria, fungi, and plants for future structure-based in-
hibitor development programs.
The technical advances occurring in the field of cryo-electron
microcopy (EM) has resulted in the resolution expectations for
single-particle EM reconstructions to be significantly improved
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with, for example, the number of sub 4 Å structures in the Electron
Microscopy Data Bank (EMDB) rising from 32 to 171 between
2012 and 2014 (11). This improvement in resolution has opened the
door to a host of research directions gained by single-particle cryo-
EM experiments. One such example is rational inhibitor design (12,
13), a field previously driven by X-ray crystallography and NMR
data, but that more recently has seen cryo-EM used to determine
structures of the TRPA1 ion channel, the proteasome, p97, the 80S
ribosome, and β-galactosidase in complex with their respective in-
hibitors (14–18).
Here we present single-particle cryo-EM structures of At_IGPD
and Sc_IGPD in complex with C348 to global resolutions of 3.1 and
3.2 Å, respectively. The core of each complex displays higher local
resolution, permitting de novo building and the identification of both
the bound inhibitor and coordinating metal ions, with the At structure
validated through a corresponding X-ray structure (PDB ID: 5EKW)
(5). Importantly, clear structural differences could be seen between
the At and Sc IGPD homologs that may account for the significant
differences seen between the binding affinities of potent inhibitors.
Results and Discussion
Grids of both Sc_IGPD and At_IGPD in complex with an excess
of the racemate of C348 displayed good ice thickness, with the
particles having a distinct square shape. For At_IGPD, swarm
picking was performed in EMAN2 (19), resulting in 110,977 particles.
For Sc_IGPD, autopicking was carried out using RELION, resulting
in 365,498 particles. For both enzymes, the resulting 2D classes in
RELION provided clear structural detail, indicative of a high-resolution
data set (Fig. 1 A and B). 3D refinement was performed on particles
belonging to the best 2D classes in RELION (20), with the resolution
further improved through the removal of bad particles through iterative
2D and 3D classification and also cutting back the dose to∼20 e−/Å2 in
the case of At_IGPD. The final EM maps have a global resolution of
3.1 and 3.2 Å (Fig. S1), with a higher resolution within the core of the
map of 2.9 and 3.1 Å, respectively, for At_IGPD and Sc_IGPD (Fig. 1
C and D). In both structures, the resulting maps showed clear and
continuous density for the protein backbone and side chains (Fig. 1 E
and F). For theAt_IGPD/C348 complex, the EM-derived density map
was of sufficient quality to carry out de novo model building in Coot
(21, 22), with the resulting model clearly identifying four helical
components and eight β-strands within each subunit, which were
arranged in a 24-mer with 432 symmetry (Fig. 2 A and B). For
Sc_IGPD, the structure was built by docking a homology model based
on At_IGPD into the EM map before rebuilding any unconserved
amino acid sidechains and fitting the loop regions. The quality of the
EMmap for both structures permitted the identification of side chains
and the ability to trace the sequence with confidence (Fig. 1 E and F).
To identify any regions of unexplained density within the
At_IGPD map, which would account for any intrinsically bound
ligands, the protein model was filtered to the same resolution as
the EMmap, and a difference map between the EMmap and the
At_IGPD model was generated. Two significant areas of positive
density were present in the difference map located within the
active site of the enzyme, which, based on evidence from previous
studies (3, 5, 23), account for the inhibitor and a pair of manga-
nese ions (Fig. 2C). The metal ions were modeled into the two
strongest peaks in positive difference density within two clusters of
histidine and glutamate residues (His47, His73, His74, His145,
His169, His170, Glu173, and Glu77) that octahedrally coordinate
each metal ion with positions ∼2.2 Å away. The remaining density
accounted for the inhibitor, and although the resolution of the EM
map was not sufficient to assign the pose or stereochemistry, the
approximate orientation and location of the inhibitor could be
modeled (Fig. 2D). The negatively charged phosphonate group of
C348 is located within a cavity surrounded by a cluster of positively
charged residues: Arg99, Arg121, and Lys177. The lone pairs of
the 1,2,4-triazole ring nitrogen atoms of the inhibitor occupy a
position close (∼2.6 Å) to both Mn2+ ions, suggesting they could
complete the coordination sphere of each metal ion. The docked
inhibitor and Mn2+ ions were then subject to refinement in PHENIX
(24), using the symmetrized 24-mer.
To assess the validity of the At_IGPD EM model, it was
compared with a previously determined 1.1 Å crystal structure of
the same complex (PDB ID: 5EKW) (5). The structures were
superimposed using GESAMT superpose in CCP4 (25) with a
rmsd value of 0.7 Å (Fig. 2E). Conformational differences be-
tween the two structures are concentrated within the loop re-
gions (residues Pro131 to Asp139 and Asp190 to Lys201), which
could reflect differences in the model building resulting from the
lower resolution of the EM map. Comparisons of the inhibitor
binding region showed similarities with regard to the positioning of
the bound inhibitor and the pattern of coordination around the
metal ions (Fig. 2F), with small differences in the side chain position
of the coordinating histidine residues (Fig. 2F) accounted for by the
lower resolution of the EM structure. In the At_IGPD/C348 crystal
structure, the C-terminal 15 residues of each subunit form interac-
tions with the phosphonate group of the inhibitor via the side chains
of Ser199 and Lys201. This interaction is also conserved in the
complexes of an inactive mutant (E21Q) of At_IGPD2 in complex
with substrate (PDB ID: 4MU4) (3), where the position of the loop
buries the active site from solvent. Mutations that truncate IGPD at
the C terminus, removing the loop, render the enzyme inactive,
suggesting the interaction of the C-terminal loop with the active site
is critical for activity (5). The C-terminal loop can be seen as a weak
feature in the At_IGPD EMmap and was not of sufficient quality to
Fig. 1. The cryo-EM structure of both At_IGPD and Sc_IGPD. Representative
2D class average (Left) and a slice through from the final 3D reconstruction
showing the internal β-strands (Right) for At_IGPD (A) and Sc_IGPD (B). 3D
reconstruction colored by local resolution (determined within RELION) for
At_IGPD (C) and Sc_IGPD (D) (color key is shown on the right and approxi-
mate dimensions above). Example of the density in the EM maps for the
equivalent region in At_IGPD (E; blue carbon atoms) and Sc_IGPD (F; green
carbon atoms); note the different shape of the density for the Ile (At_IGPD)
and Val (Sc_IGPD) residue. In E and F, nitrogen, oxygen, and sulfur atoms are
colored blue, red, and yellow, respectively.
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permit the unambiguous modeling of this loop region. The weak
density likely represents the averaging of multiple positions of the
loop on each enzyme subunit on freezing the sample.
Both the crystal structure and EM structure were determined
in the presence of a mix of R and S forms of the inhibitor. In the
crystal structure, both enantiomers could be interpreted within
the electron density map at the resolution obtained, which showed
that they bind with mirror-image packing (5). However, the cor-
responding EM map does not offer this level of detail because of
the lower resolution, and therefore we cannot assess the ratio of
R and S isomer binding.
To assess the possible role of radiation damage on the pose of
the bound inhibitor, the At_IGPD map was generated with a sig-
nificantly reduced electron dose. This was achieved by reducing the
number of frames used for the reconstruction, with the particle
number remaining constant. The lowest dose that was useable be-
fore significant loss of resolution was ∼12 e−/Å2, which produced an
equivalent map of 3.25 Å global resolution. Although the lower
dose map had stronger features for some of the negative side chains
(Fig. S2), the resulting density about the inhibitor binding domain
did not show any significant difference between the high- and low-
dose map, with a local resolution in this area of 2.9 Å.
After the successful structure determination of At_IGPD, we
also studied Sc_IGPD by single-particle cryo-EM, which has thus
far been intractable to structure determination by crystallogra-
phy because of the diffraction limit of the crystals being ∼6 Å (9).
The sequence identity between At_IGPD and Sc_IGPD is 42%,
with 54% of residues being similar or identical (Fig. S3). For the
16 residues that make up the inhibitor binding site, 14 are fully
conserved with changes in Gln51Ala and Ser54Lys (At_IGPD
numbering). The most significant difference between the two
homologs is a 24-amino acid insertion between β2 and β3 in
Sc_IGPD, which seems to be a unique feature of IGPD homo-
logs from budding yeast. The single-particle EM map of
Sc_IGPD at 3.2 Å resolution showed that the enzyme has the
same overall architecture made up of a four-α-helical bundle
flanked by a four-stranded β-sheet on either side (Fig. 3A). Each
monomer is arranged in a 432 symmetrical 24-mer, consistent
with other members of the IGPD family (4, 23), with a larger
overall size compared with At_IGPD resulting from the addi-
tional 24-amino acid insert on the surface of Sc_IGPD situated
between β2 and β3 (Fig. 3B). Comparison of the overall fold for
both Sc_IGPD and At_IGPD shows close similarity with an rmsd
of 0.9 Å (Fig. 3C). In addition to the region between β2 and β3,
Fig. 2. Analysis of the inhibitor binding pocket and
comparison with a representative crystal structure of
At_IGPD. (A) Ribbon diagram showing the final
model of the At_IGPD monomer colored blue to red
from N to C termini, with secondary structure labeled.
(B) Ribbon diagram of the full At_IGPD 24-mer, with
each subunit colored differently. (C) Positive density
within the difference map (green surface) generated
by subtracting the map of the de novo built At_IGPD
structure from the At_IGPD EM map. This resulted in
strong density only within the active site and flanking
region, with no other area of significant density not
accounted for by the de novo built model. The in-
hibitor, C348, is shown as sticks, with blue carbon
atoms within the difference map. Note that C348 sits
within a subunit interface, with the pocket partly
formed by α4 from two different subunits. (D) Fitting
of C348 within the active site of IGPD, showing strong
density that accommodates both the inhibitor and
the two Mn2+ ions (purple spheres). (E) A superposi-
tion of the At_IGPD structure as derived from EM
(blue) and X-ray crystallography [yellow; PDB ID:
5EKW (5)], shown in ribbon format. The conforma-
tion of the secondary structure elements within
monomer is largely identical, with only minor con-
formational differences observed within the loop
regions. (F) The inhibitor binding pocket of the EM
and X-ray crystallography-derived models, colored as
in E with key residues and inhibitor shown in stick
format. Mn2+ ions are shown as purple (EM) or green
(X-ray) spheres. In all parts, nitrogen, oxygen, and
phosphorous are colored blue, red, and orange, re-
spectively.
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the C-terminal substrate binding loop, which is also involved in
inhibitor binding, is better resolved within the Sc_IGPD struc-
ture compared with At_IGPD, permitting all but the final Met
residue in the C-terminal loop to be built (Fig. 3 D and E). The
inhibitor binding site, as with At_IGPD, shows clear density for
the bound inhibitor, surrounding side chain residues and co-
ordinating metal ions, allowing it to be unambiguously placed
within the binding site (Fig. 3F).
Intriguingly, enzyme assays have shown that C348 is a more
potent inhibitor of Sc_IGPD (0.6 nM Ki) (2) than of At_IGPD
(∼25 nM Ki) (5), but a structural basis for this difference has not
been determined. To better understand this difference, the po-
sition of the residues that flank the inhibitor biding site were
compared in each structure, showing no significant difference
(Figs. 2D and 3F and Fig. S4A). All but two residues that form
the inhibitor binding site are fully conserved between Sc and
At_IGPD, with the changes in Gln51Ala and Ser54Lys being
distant from the bound inhibitor (Fig. S4 B and C). The quality
of the map density for the inhibitor and the metal ions is also
consistent between the two structures. Therefore, with the se-
quence and structural conservation within the binding site be-
tween the At_IGPD and Sc_IGPD, the difference in inhibitor
potency does not seem to be directly related to those residues
that make up the inhibitor binding pocket. It is interesting to
note that the replacement of Ala and Ile for Cys at position
81 and 96, respectively, within Sc_IGPD places two cysteine
residues within a distance compatible for a disulphide bond. This
is consistent with studies that have shown β-mercaptoethanol to
be required for activity of Sc_IGPD (8). However, there is no
evidence within the EM-derived map to show the presence of a
disulphide bond (Fig. S5).
The EM map clearly indicates the position of the 24-amino
acid insertion between β2 and β3 in Sc_IGPD, which lies on the
outside face of each subunit, surrounding the spherical particle
(Fig. 3 A and B). The EM map for this loop region permits 19 of
the 24 amino acids to be modeled (Fig. 4A). However, there is
significant ambiguity in the location of Ser39 to Val43, where the
EM map density is at its weakest and does not enable the full
path of the main chain to be determined. To better define this
poorly resolved region, comparative modeling was conducted
with Rosetta (26, 27), which showed a consistent positioning of
Ser39 to Val43 within the map (Fig. S6). The surface loop
emerges from β2 (Gly-25 to Ile-34) and folds back over the
surface of the external β-sheet, forming a strip of hydrophobic
packing interactions with the surface residues on β2 and β3 (Figs.
3A and 4A). The loop then becomes less defined, with residues
Pro36 to Val43 unresolved within the map. The loop then forms
a β-strand adjacent to β3 on the external β-sheet before rejoining
the structure at β4 (Fig. 4A). This structural arrangement pre-
sents a highly charged –EKEAEAVAEQ–motif on the surface
loop, the role for which remains to be determined. This addi-
tional loop region is a feature specific to the fungal IGPD
family, and multiple sequence analysis shows it can vary from 24
(Saccharomyces) to 42 amino acids in, for example, Penicillium
and Aspergillus species (Fig. S7). Overall, there is poor con-
servation across the different homologs, but it’s interesting to
note that strong sequence conservation is observed around the
negatively charged region that forms the additional β-strand,
Fig. 3. Analysis of the Sc_IGPD structure and comparisons to At_IGPD. (A) A ribbon diagram of the Sc_IGPD monomer colored blue to red from the N to C
termini and with secondary structure labeled. (B) Ribbon diagram of the full At_IGPD 24-mer, with each subunit colored differently. (C) Superposition of the
At_IGPD (blue) and Sc_IGPD (green) structures, shown in ribbon format, with the additional 24-residue loop region in the later shown above the N-terminal
β-sheet. (D) Density within the At_IGPD EM map around the C-terminal domain showing weak density for this region. (E) The C-terminal loop region of
Sc_IGPD, which can be unambiguously assigned within the EM map. Both D and E are shown in an equivalent view with the same map contouring level.
(F) Fitting of C348 within the active site of IGPD, showing strong density that accommodates the inhibitor, surrounding residues, and the two Mn2+ ions
(purple spheres).
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suggesting this may be a conserved feature across the dif-
ferent fungal species.
In addition to the loop insert between β2 and β3 in Sc_IGPD,
a further difference is seen for the C-terminal loop, which has
been shown to be important for substrate and inhibitor binding.
The C-terminal loop is poorly defined in the At_IGPD EM map,
but in Sc_IGPD, the position of the C-terminal loop is better
resolved and could be modeled, despite both structures being at
equivalent resolutions (Figs. 3 D and E and 4B). Analysis of the
position and conformation of the C-terminal loop in Sc_IGPD
shows that it sits adjacent to the part of the extended surface
loop that forms the additional β-strand on the external β-sheet.
Moreover, Gln46, which is at the end of the additional β-strand,
is positioned such that it could form a hydrogen bond with the
backbone carbonyl of Thr215. Additional interactions could be
made between Ser50 and Asp211. Importantly, Gln46 is fully
conserved between the different fungal species, and position
50 varies between a Ser and Thr residue, both of which could
make hydrogen bond interactions. Therefore, the extended sur-
face loop may act as a “latch” to the active site, stabilizing the
C-terminal substrate/inhibitor binding loop; this is why it is better
resolved in the Sc_IGPD EM map and perhaps goes some way
to explaining the enzyme’s increased binding affinity for C348.
The sequence conservation between the different fungal species
may point toward this being a conserved aspect of the fungal
IGPD family.
Conclusions
IGPD catalyzes the sixth step in histidine biosynthesis and is
essential in plants and microorganisms, making it an attractive
target for antibacterial and herbicide development. Although
X-ray crystallography has been a powerful approach in de-
termining the structure of several homologs of IGPD from, for
example, A. thaliana, M. tuberculosis, and P. furiosus, it has been
unsuccessful in determining the S. cerevisiae IGPD structure.
This is crucial because the yeast homolog contains a significant
insert between β2 and β3 and is more sensitive to IGPD inhibi-
tors (2, 5). Here we have used an EM approach to determine the
3D structures of both At_IGPD and Sc_IGPD to investigate the
binding of potent inhibitors. We have shown that the difference
in inhibitor potency against the different homologs is unlikely to
be through direct changes in the inhibitor binding region. In-
stead, the position of a 24-amino acid insertion in Sc_IGPD
shows that it can form an additional β-strand and potentially
make hydrogen bonding interactions to the C-terminal loop that
would stabilize the binding of the inhibitor and the substrate and
intermediates generated during catalysis. The presence of this
β-strand in Sc_IGPD and its absence in At_IGPD may explain
why the lead compounds are more potent inhibitors of IGPD
from S. cerevisiae and why diffraction quality crystals of Sc_IGPD
were difficult to obtain. Moreover, through sequence compari-
sons, this region has been shown to be conserved in fungal species,
and although variable in length, those residues that interact with
the C-terminal loop and form the additional β-strand are highly
conserved, suggesting this feature is common within fungi. This is
important both in the design of antifungal therapies and in un-
derstanding the basic biology of this important class of proteins.
The use of cryo-EM as a high-resolution structural technique
has been shown during the last 5 years with a diverse range of
proteins and protein complexes determined to sub 4 Å, with
some now breaking the 2 Å barrier (28). Therefore, EM can now
be used to directly visualize inhibitor binding and is a powerful
approach for those systems intractable to other techniques; for
example X-ray crystallography (17). Moreover, by being able to
de novo build the structure and identify the bound inhibitor, the
EM studies are not dependant on other structural techniques to
provide initial models. Structural biology can underpin thera-
peutic design, and it is becoming clear that with advances in EM,
this can also become a complementary approach to developing a
toolkit for structure-based drug design.
Methods
Protein Production. At_IGPD was produced and purified using procedures
previously published (3, 5). The gene encoding for S. cerevisiae IGPD (HIS3)
was cloned into a pET vector and transformed into a BL21 (DE3) expression strain
of Escherichia coli cells (Novagen). Protein expression was performed at
37 °C by induction with 1 mM isopropyl-b-D-thiogalactopyranoside in Luria
Broth supplemented with 5 mM MnCl2 at the point of induction. Cells were
harvested by centrifugation (5,000 × g), and pellets were frozen at −80 °C.
For purification, 2 g cell paste was defrosted in buffer A (50 mM Tris·HCl at
pH 8.0) and disrupted by ultrasonication (3 × 20 s bursts). Cell debris was
removed by centrifugation at 70,000 × g for 10 min. Cell-free extract was
applied on a 5-mL DEAE Fast Flow cartridge (GE Healthcare). Elution
was performed by a 50-mL gradient of NaCl from 0 to 0.5 M concentration
in buffer A. Fractions containing Sc_IGPD were combined, and the enzyme
was precipitated by addition of 1.7 M ammonium sulfate (0.75 mL of 4 M
ammonium sulfate was added per milliliter of protein solution). The pellet
was collected by centrifugation (5 min at 45,000 × g) and then dissolved in
2 mL buffer A and applied on a gel filtration column 16 × 600 HiLoad
Superdex200 that had been equilibrated with buffer A + 0.5 M NaCl. Gel
filtration was performed at flow rate 1.5 mL/min and 2-mL fractions of
the 24-mer of Sc_IGPD (∼500 kDa MW) were combined. Purity of the
preparation was about 90%, as estimated by SDS/PAGE, and yield was
about 5 mg/g cells. The protein was concentrated in elution buffer to 9 mg/mL
and later diluted to 0.5 mg/mL with 50 mM Tris at pH 8 before the inhibitor,
C348 (pH adjusted to 7.5 in water), was added to a final concentration
of 5 mM.
EM. Grids of both At_IGPD and Sc_IGPD were prepared by adding 0.5 mg/mL
IGPD/inhibitor complex to a 2:2 Quantifoil grid that had been glow dis-
charged for 20 s before use. Grids were blotted and frozen using a Vitrobot
Mark IV with 6-s blot time and a force of 6. Data were collected on an FEI
Titan Krios microscope operating at 300 kV.
At_IGPD data were collected at 75,000× magnification, corresponding
to 1.075 Å/pix sampling on a Falcon II 4 k × 4 k direct detector with
32 frames per micrograph. Data were automatically collected within a
defocus range of 1.0 and 3.5 μm, using SerialEM (29). Six hundred and
eighty-two micrographs were collected, with those displaying a high
degree of astigmatism or defocus removed from data processing. Data
were drift corrected in MotionCor (30) (Motioncor2 was not available at
the time of data processing) before defocus calculations in CTFFIND4 (31).
Fig. 4. Insertion loop in Sc_IGPD. (A) The 24-residue insertion loop in
Sc_IGPD, situated between β2 and β4 colored in purple and the C-terminal
inhibitor/substrate binding loop is shown in gray. The insertion (purple)
within Sc_IGPD lies next to the C-terminal substrate/inhibitor binding loop
(gray), possibly stabilizing the interaction. The 24-residue insert in Sc_IGPD
compared with At_IGPD forms an additional β-strand (β3) between A44 and
Q46, and therefore there is one extra strand within its external β-sheet.
Residues between K38 and A44 are not well resolved within the EM map,
and have not been modeled, and some residues in the loop region have
been truncated because of poor side chain density. (B) The equivalent view
in At_IGPD with a much smaller loop between β2 and β3, which is well de-
fined in the EM map (shown in purple). The C-terminal loop (gray) is more
poorly defined and makes no interactions with the loop region between
β2 and β3.
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Particles were picked using the swarm function in EMAN2, with a box size
of 180 resulting in 110,977 particles (19). 2D classification within RELION
was used to sort the data, with 83,446 particles belonging to well-defined
classes, which displayed clear secondary structure (20). Subsequent 3D
classification into two classes gave one good-quality class, with the other
resulting in a poorer reconstruction with no signs of an alternative
conformational state. 3D classification resulted in a final dataset of
55,481 particles.
Sc_IGPD data were collected automatically, using EPU with a Falcon III
detector operating in linear mode at a magnification corresponding
to 1.065 Å/pix, with a total dose of ∼50 e−/Å2. Then, 2,827 micrographs
were collected and drift correction and dose weighting carried out in
MotionCor2 and defocus estimation in Gctf (32, 33). Automated particle
picking was carried out in RELION 2.0, resulting in 365,498 particles. Particles
from the center of 2D lattices were removed via 2D classification, leaving
61,480 particles. Subsequent 3D classification into three classes gave one-
good quality class, with the other two resulting in poorer reconstructions with
no signs of an alternative conformational state. 3D classification resulted in a
final dataset of 11,560 particles.
Model Building, Refinement, and Validation. For At_IGPD, secondary structure
assignment was initially conducted in silico, using Buccaneer (21) using a
segmented map that represented only one of the 24 subunits to reduce
computation time. Visual inspection of this model in Coot was used to cor-
rect for any clear errors in connectivity, assign unbuilt residues, and alter
incorrectly built rotamers (22). Independently for additional validation, de
novo model building was also carried out within Rosetta3 (26, 27), producing
a consistent fold with all core helices well modeled. On completion of the
model, clear density could be identified, which was not part of the peptide
chain and was designated as inhibitor and metal density. The inhibitor and
metals were subsequently fitted by hand, assuming standard bond length
and geometry for the metals and bound inhibitor. The completed model
containing the inhibitor was then symmetrized into the map, using UCSF
Chimera (34), and refined against the map, using PHENIX real space re-
finement (24, 35). Maps were locally filtered within RELION for model
building and map analysis.
For Sc_IGPD, a homology model was generated using Phyre2 1:1 thread-
ing based on the EM-derived At_IGPD structure (36). The model was cor-
rected by hand in COOT, and the additional loop region was added, before
real space refinement within PHENIX (for refinement statistics, refer to
Tables S1 and S2). Missing residues Ser39 to Val43 were modeled using the
comparative modeling tool in Rosetta (26, 27) to generate an ensemble of
100 models that were then scored and sorted.
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